Xilio Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Xilio Therapeutics, Inc. (XLO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 10.68 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.06M shares, a 1277.57% increase year-over-year.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 802.81K shares, a 90.11% decline year-over-year.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 8.12M shares, a 31.15% increase year-over-year.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 6.19M shares, a 22.66% increase year-over-year.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 11.02M shares, a 1648.06% increase from fiscal 2024.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 630.42K shares, a 91.63% decline from fiscal 2023.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 7.53M shares, a 48.09% increase from fiscal 2022.
- Xilio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.09M shares, a 21.06% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 10.68M shares 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | 11.06M shares 10-Q · filed 2026-05-12 | ||||||
| 2025-12-31 | 11.02M shares 10-K · filed 2026-03-23 | ||||||
| 2025-09-30 | 211.94M shares 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | 15.13M shares 10-Q · filed 2026-08-12 | 211.85M shares 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | 802.81K shares 10-Q · filed 2026-05-12 | 11.24M shares 10-Q · filed 2025-05-08 | |||||
| 2024-12-31 | 630.42K shares 10-K · filed 2026-03-23 | 8.83M shares 10-K · filed 2025-03-11 | |||||
| 2024-09-30 | 8.49M shares 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | 8.52M shares 10-Q · filed 2025-08-14 | ||||||
| 2024-03-31 | 8.12M shares 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | 7.53M shares 10-K · filed 2025-03-11 | ||||||
| 2023-09-30 | 7.90M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 6.06M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 6.19M shares 10-Q · filed 2024-05-14 | ||||||
| 2022-12-31 | 5.09M shares 10-K · filed 2024-04-01 | ||||||
| 2022-09-30 | 5.07M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 5.26M shares 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 5.05M shares 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | 4.20M shares 10-K · filed 2023-03-02 | ||||||
| 2021-09-30 | 21.93M shares 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | 21.84M shares 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | 21.43M shares 10-Q · filed 2022-05-12 | ||||||
| 2020-12-31 | 8.13M shares 10-K · filed 2022-03-01 | ||||||
| 2020-09-30 | 8.22M shares 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |